{"entity":{"id":"nct04771130","kind":"trial","name":"A Study of BGB-11417 in Participants With Myeloid Malignancies","aka":[],"tldr":"A phase 1/2 trial of Sonrotoclax and Azacitidine in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by BeOne Medicines, now recruiting.","summary":"A Study of BGB-11417 in Participants With Myeloid Malignancies is a phase 1/2 interventional study registered as NCT04771130 by BeOne Medicines, with 260 participants planned, started 2021-05-24 and due to reach its primary completion in 2028-08-31. Interventions recorded: BGB-11417, Azacitidine and Posaconazole.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04771130","url":"https://clinicaltrials.gov/study/NCT04771130"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":["bcl2-inhibitors","kinase-inhibitors"],"targets":[],"drugs":["sonrotoclax","azacitidine"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04771130","phase":"1/2","setting":"A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies","sponsor":"BeOne Medicines","participation":[{"nct":"NCT04771130","source":"https://clinicaltrials.gov/study/NCT04771130","fetchedAt":"2026-10-07T16:53:26.644Z","studySha256":"de06564251523aef98c063b7b867745613a7c331275f04aaed8a3d04fb0f98f9","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-14","leadSponsor":"BeOne Medicines","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":260,"enrolmentType":"ESTIMATED","siteCount":47,"recruitingSiteCount":42,"countries":["Australia","China","France","Germany","Italy","New Zealand","South Korea","Spain","United Kingdom","United States"]}],"started":"2021-05-24","startedType":"actual","enrolled":260,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04771130/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}